CD8A and neoplasm: We isolated spleens from mice primed with avelumab (versus PBS) and compared the phenotype and abundance of CD8+ T cells 72 h after B16-OVA tumor injection (day 10 overall) with a large panel of T cell markers via CyTOF (Fig. 5A, Supplemental Table I).